Novartis News

Novartis, the world's sixth largest drug maker, reported a double-digit net profit rise on Thursday and forecasted a sustained growth for this year despite the increasingly difficult global market.

Befitting the uncertain outlook that many investors have for the drug sector, Swiss drug giant Novartis (NYSE: NVS) reported mixed results on Thursday morning.

Novartis AG, Europe s fourth-biggest drugmaker, reported the slowest profit growth in five quarters after $120 million in charges, including settling a U.S. Justice Department investigation and restructuring ...

The best part of following the drug industry is watching a company develop a product that genuinely helps people.

Amphora Discovery Corp., a Durham-based biotechnology firm that owns technology designed to speed up the process of drug discovery, has raised $20 million in a third round of financing.

The Novartis Foundation for Sustainable Development (NFSD) today reinforced its 25-year commitment to sustainable development and stakeholder-dialogue with a landmark symposium exploring the roles and ...

Story in full NOVARTIS has temporarily withdrawn its application for European Union approval of its new-generation painkiller Prexige following safety fears over Merck & Co - s similar drug Vioxx.

Novartis AG is expected to announce plans this week to restructure and potentially relocate its generic drug subsidiary Sandoz, according to the Financial Times.

The Food and Drug Administration agreed Friday to allow a drug currently used against advanced breast cancer to be prescribed to prevent the disease from recurring in women who have been treated for early forms ...

With massive competitors such as Pfizer (NYSE: PFE) , Novartis AG (NYSE: NVS) , and even Merck (NYSE: MRK) , life can be tough for the smaller players in the pharma business, such as for Belgian company UCB.

Paradise is the name of a certain male strip club on the fringe of the MIT campus.

Novartis Pharma AG announced that Visudyne (verteporfin), currently the only treatment for some forms of "wet" Age-Related Macular Degeneration (AMD), was launched today in Japan.

Emisphere Technologies' (Nasdaq: EMIS) popularity soared yesterday after the company announced that Novartis (NYSE: NVS) agreed to a licensing deal to develop an experimental oral formulation of recombinant ...

Results of two separate Phase III studies involving Enablex(TM) (darifenacin hydrobromide), an M3 selective receptor antagonist (M3 SRA) being developed for the treatment of overactive ...

DESPITE assurances from president Jacques Chirac at the outset of Sanofi-Synth labo - s hostile bid for Aventis in January that any deal should be purely a private-sector affair, the ...

More than 7.4 million Medicare enrollees will participate in the drug discount card programs, according to the Center for Medicare & Medicaid Services.

Novartis, the Swiss drugs group, edged a step closer yesterday to swallowing its Basel neighbour Roche when it announced it had raised its stake in the secretive, family-run firm to 33.3% - just below ...

Swiss pharmaceutical giant Novartis AG said net income in the fourth quarter rose 14.6 percent, boosted by strong product revenues.

Unigene Laboratories, Inc. (OTCBB: UGNE) has signed licensing and clinical supply agreements with Novartis Pharma AG (NYSE: NVS) to provide for the recombinant production of calcitonin, ...

Novartis AG, Europe's third-biggest drugmaker, boosted 2003 net profit by six percent to an in-line $5.02 billion and on Thursday forecast more record earnings in 2004 despite continued pressure on ...

It also said it increased slightly its ownership in rival Roche Holding AG, reviving speculation of a takeover attempt.

Novartis AG, Europe s third-largest drugmaker, said profit rose 15 percent in the final quarter of 2003 and predicted higher 2004 earnings as it gains market share.

Novartis will donate the drugs to the Global Drug Facility, which is hosted by WHO and operated by the Stop TB Partnership.

Swiss drug firm Novartis signed an accord with the World Health Organisation (WHO) on Friday to treat 100,000 tuberculosis patients a year free of charge for five years.

Half a million of the world"s poorest tuberculosis patients are to benefit from free life-saving drugs under an agreement signed today by the World Health Organization (WHO) and the pharmaceutical ...